Brief: Cyclerion Announces CY6463 Clinical Pipeline Progress, Q2 Results

Korsana Biosciences

09/08/2022 21:39

Aug 9 (Reuters) - Cyclerion Therapeutics Inc  CYCN.O :
    * CYCLERION ANNOUNCES CY6463 CLINICAL PIPELINE PROGRESS AND
SECOND
QUARTER 2022 FINANCIAL RESULTS
    * CYCLERION THERAPEUTICS INC - STUDY IN ALZHEIMER'S DISEASE
WITH
VASCULAR PATHOLOGY (ADV) ENROLLMENT ONGOING
    * CYCLERION THERAPEUTICS INC - POSITIVE TOPLINE RESULTS FOR
CY6463
ANNOUNCED IN TWO CLINICAL STUDIES IN PATIENTS WITH MITOCHONDRIAL
ENCEPHALOMYOPATHY
    * CYCLERION THERAPEUTICS INC - NET LOSS WAS APPROXIMATELY
$13.4
MILLION FOR Q2

Source text for Eikon:  ID:nGNX99flwR 
Further company coverage:  CYCN.O 

 ((Reuters.Briefs@thomsonreuters.com;))